Status:
TERMINATED
Phase 2A Open Label Safety Study of Fovista® (Anti-PDGF BB) Regimen Administered in Combination With Anti-VEGF Therapy to Study Sub-Retinal Fibrosis in Neovascular AMD
Lead Sponsor:
Ophthotech Corporation
Conditions:
Age-related Macular Degeneration
Eligibility:
All Genders
50+ years
Phase:
PHASE2
Brief Summary
The objective is to evaluate the safety of intravitreal Fovista® (anti-PDGF BB) administered in combination with anti-VEGF therapy.
Detailed Description
The objective is to evaluate the safety of intravitreal Fovista® (anti-PDGF BB) administered in combination with anti-VEGF therapy in either a "Simultaneous" Regimen (Fovista® administered with anti-V...
Eligibility Criteria
Inclusion
- Subjects of either gender aged ≥ 50 years
- All fluorescein angiographic subtypes with presence of active choroidal neovascularization
Exclusion
- Any intraocular surgery or thermal laser within three (3) months of trial entry. Any prior thermal laser in the macular region, regardless of indication
- Subjects with subfoveal scar or subfoveal atrophy
- Any ocular or periocular infection in the past twelve (12) weeks
- History of any of the following conditions or procedures in the study eye: Rhegmatogenous retinal detachment, pars plana vitrectomy, filtering surgery (e.g. trabeculectomy), glaucoma drainage device, corneal transplant
Key Trial Info
Start Date :
July 1 2014
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 1 2016
Estimated Enrollment :
101 Patients enrolled
Trial Details
Trial ID
NCT02214628
Start Date
July 1 2014
End Date
December 1 2016
Last Update
February 23 2024
Active Locations (13)
Enter a location and click search to find clinical trials sorted by distance.
1
Phoenix, Arizona, United States, 85014
2
Beverly Hills, California, United States, 90211
3
Sacramento, California, United States, 95819
4
Sacramento, California, United States, 95841